8-K: Current report filing
Published on May 7, 2001
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) May 7, 2001
------------
COMMONWEALTH BIOTECHNOLOGIES, INC.
----------------------------------
(Exact Name of Registrant as Specified in Charter)
601 Biotech Drive, Richmond, Virginia 23235
------------------------------------- -----
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (804) 648-3820
---------------
N/A
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On February 14, 2001, Commonwealth Biotechnologies, Inc. (the "Registrant")
filed a provisional patent application, Docket No. 006338-017 (captioned
Adsorption and Removal of Endotoxin from Physiological Fluids Using Cationic
- ----------------------------------------------------------------------------
Helix Peptides), with the United States Patent and Trademark Office to protect
- -------------
compounds related to the treatment of sepsis.
Any statements contained in this report that relate to future plans, events or
performance are forward-looking statements that involve risks and uncertainties
as identified in the Registrant's filings with the Securities and Exchange
Commission. Actual results, events or performance may differ materially.
Readers are cautioned not to place undo reliance on these forward-looking
statements, which speak only as the date hereof. The Registrant cannot
guarantee that the provisional patent application will evolve into a new patent
for the Registrant or that the compounds protected by the provisional patent
application or any of the Registrant's other intellectual properties will ever
be commercialized or profitable. The Registrant undertakes no obligation to
publicly release the results of any revisions to these forward-looking
statements that may be made to reflect the events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
COMMONWEALTH BIOTECHNOLOGIES, INC.
By: /s/ Richard J. Freer, Ph.D.
-------------------------------
Richard J. Freer, Ph.D.
Chairman
May 7, 2001
3